R&D | November 14, 2025
UK MHRA finds gut microbiome research unreliable across labs
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Fenebrutinib targets cells in the immune system known as B cells and microglia
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Relmada expects to initiate its Phase 3 program in the first half of 2026
Poviztra is a second brand of Wegovy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
